Rullan, Antonio
Marín-Jiménez, Juan A.
Lozano, Alicia
Bermejo, Oriol
Arribas, Lorena
Ruiz, Nuria
Linares, Isabel
Taberna, Miren
Pérez, Xavi
Plana, María
Oliva, Marc
Mesía, Ricard http://orcid.org/0000-0002-3785-3563
Funding for this research was provided by:
Merck KGaA
Article History
Received: 12 February 2024
Accepted: 14 May 2024
First Online: 23 May 2024
Declarations
:
: The authors declare the following finantial interests/personal relationships which may be considered as potential competing interests. MP has received advisory honoraria from BMS and speaker honoraria from MSD. MO has received advisory honoraria from Merck, MSD and Transgene; research support from Merck and Roche; and declares clinical trial support from Abbvie, Ayala Pharmaceutical, MSD, ALX Oncology, Debiopharm International, Merck, ISA Pharmaceuticals, Roche Pharmaceuticals, Boehringer Ingelheim, Seagen and Gilead. RM has received advisory honoraria from Merck, Nanobiotix, MSD, BMS, Roche, Seatle Genetics, AZ, Pfizer, Boehringer and Seagen: speaker honoraria from Merck, MSD and Boehringer; and travel support from BMS, MSD and Merck. The authors AJ, JAM-J, AL, OB, NR, IL, MT, and XP have no relevant financial or non-financial interests to disclose.
: This study was performed in line with the principles of the Declaration of Helsinki. The entire study was approved by Hospital Universitari de Bellvitge Ethics Committee under the approval number AC112/15. All the participants provided written informed consent prior to their inclusion in the study.